PE20151518A1 - Administracion transmucosa de tocotrienol - Google Patents
Administracion transmucosa de tocotrienolInfo
- Publication number
- PE20151518A1 PE20151518A1 PE2015000622A PE2015000622A PE20151518A1 PE 20151518 A1 PE20151518 A1 PE 20151518A1 PE 2015000622 A PE2015000622 A PE 2015000622A PE 2015000622 A PE2015000622 A PE 2015000622A PE 20151518 A1 PE20151518 A1 PE 20151518A1
- Authority
- PE
- Peru
- Prior art keywords
- transmucose
- tocotrienol
- exercise
- levels
- muscle pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A COMPOSICIONES FARMACEUTICAS DE ADMINISTRACION TRANSMUCOSA, PARTICULARMENTE SUBLINGUAL, QUE COMPRENDE AL MENOS UN TOCOTRIENOL O DERIVADO DEL MISMO JUNTO CON UNO O MAS EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. SE REFIERE ADEMAS AL USO DE DICHAS COMPOSICIONES PARA TRATAR O PREVENIR EL DOLOR MUSCULAR DESPUES DEL EJERCICIO, EL DOLOR MUSCULAR DE INICIO RETARDADO, LA FIBROSIS CARDIACA, LA HIPERTENSION, LA INFLAMACION, EL ICTUS, EL CANCER, LOS NIVELES ELEVADOS DE COLESTEROL Y/O TRIGLICERIDOS, LA CALVICIE, LA HIPERTROFIA, AFECCIONES QUE RESULTAN DE LA EXPOSICION A RADIACION, ESTABILIZACION Y/O CONTROL DE LOS NIVELES DE GLUCEMIA Y MEJORA DE LA RESISTENCIA AL EJERCICIO Y LA CAPACIDAD PARA REALIZARLO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904937A AU2012904937A0 (en) | 2012-11-13 | Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents | |
| AU2012905406A AU2012905406A0 (en) | 2012-12-11 | Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151518A1 true PE20151518A1 (es) | 2015-11-25 |
Family
ID=50730398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000622A PE20151518A1 (es) | 2012-11-13 | 2013-11-13 | Administracion transmucosa de tocotrienol |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10675265B2 (es) |
| EP (1) | EP2919777B1 (es) |
| JP (3) | JP6460998B2 (es) |
| KR (1) | KR20150082109A (es) |
| CN (2) | CN104582700B (es) |
| AU (1) | AU2013344817B2 (es) |
| BR (1) | BR112015010703B1 (es) |
| CA (1) | CA2891164C (es) |
| DK (1) | DK2919777T3 (es) |
| ES (1) | ES2778065T3 (es) |
| HK (1) | HK1207295A1 (es) |
| IL (1) | IL238727A0 (es) |
| IN (1) | IN2015DN04006A (es) |
| MY (1) | MY177940A (es) |
| NZ (1) | NZ628963A (es) |
| PE (1) | PE20151518A1 (es) |
| PH (1) | PH12015501048A1 (es) |
| PL (1) | PL2919777T3 (es) |
| PT (1) | PT2919777T (es) |
| RU (1) | RU2015120181A (es) |
| SG (1) | SG11201503640WA (es) |
| WO (1) | WO2014075135A1 (es) |
| ZA (1) | ZA201504191B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| RU2015120181A (ru) * | 2012-11-13 | 2017-01-10 | Гордаген Фармасьютикалз Пти Лтд | Чресслизистая доставка токотриенола |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| WO2016069475A1 (en) | 2014-10-27 | 2016-05-06 | Aseko, Inc. | Subcutaneous outpatient management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| US20170128412A1 (en) * | 2015-08-11 | 2017-05-11 | Satoru Sugiyama | System and method for improved blood circulation and maintaining mitochondrial energy production |
| JP6858751B2 (ja) | 2015-08-20 | 2021-04-14 | アセコー インコーポレイテッド | 糖尿病管理療法アドバイザ |
| WO2019032685A1 (en) * | 2017-08-08 | 2019-02-14 | Robert John Petcavich | FORMULATIONS FOR THE CONTRIBUTION OF TREHALOSE STIMULATING AUTOPHAGIA |
| AU2021392309A1 (en) * | 2020-12-04 | 2023-07-20 | Invictus Biotechnology Pty Ltd | Transmucosal delivery of tocotrienols |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07504887A (ja) * | 1991-11-22 | 1995-06-01 | リポジェニックス，インコーポレイテッド | トコトリエノールおよびトコトリエノール様化合物ならびにこれらを使用する方法 |
| JPH0892050A (ja) | 1994-09-27 | 1996-04-09 | Lion Corp | 消臭剤及び口腔用組成物 |
| JP4271742B2 (ja) * | 1997-08-07 | 2009-06-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 免疫機能改善剤 |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| JP2001342133A (ja) * | 2000-03-31 | 2001-12-11 | Eisai Co Ltd | γ―トコトリエノール含有利尿剤 |
| AU2001242811B2 (en) * | 2000-03-31 | 2005-07-14 | Eisai R&D Management Co., Ltd. | Diuretics containing gamma-tocotrienol |
| JP2002037727A (ja) | 2000-07-26 | 2002-02-06 | Eisai Co Ltd | 脂溶性薬物を配合した速崩性固形製剤及びその製造方法 |
| JP4693140B2 (ja) * | 2000-10-06 | 2011-06-01 | 富士化学工業株式会社 | トコトリエノール含有医薬用剤 |
| US6608103B2 (en) * | 2001-02-08 | 2003-08-19 | Fuji Chemical Industry Co., Ltd. | Inhibitor for neovasculation, cell multiplication, lumen formation and FGF |
| JP4447198B2 (ja) * | 2001-02-08 | 2010-04-07 | 富士化学工業株式会社 | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| US7919525B2 (en) | 2003-02-14 | 2011-04-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Radiation protection by gamma-tocotrienol |
| EP1617724B1 (en) * | 2003-04-10 | 2014-08-20 | Barrie Tan | Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| US20050209315A1 (en) * | 2004-03-20 | 2005-09-22 | Papas Andreas M | Bioavailable nutritional supplement and method of treatment of malabsorption |
| ATE491447T1 (de) * | 2004-05-26 | 2011-01-15 | Kgk Synergize Inc | Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen |
| CN1775289B (zh) | 2004-11-15 | 2011-08-24 | 杭州赛诺菲民生健康药业有限公司 | 多维生素口腔崩解片制剂及其制备方法 |
| ES2586032T3 (es) | 2008-03-28 | 2016-10-11 | Hale Biopharma Ventures, Llc | Administración de composiciones de benzodiazepinas |
| WO2009126866A2 (en) * | 2008-04-10 | 2009-10-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Delta-tocotrienol as a radioprotective countermeasure agent |
| CA2761538A1 (en) | 2009-05-20 | 2010-12-23 | Lingual Consegna Pty Ltd | Buccal and/or sublingual therapeutic formulation |
| CA2765771A1 (en) | 2009-06-25 | 2010-12-29 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
| MX337990B (es) * | 2009-08-26 | 2016-03-30 | Edison Pharmaceuticals Inc | Metodos para la prevencion y tratamiento de isquemia cerebral. |
| US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| CA2795726A1 (en) * | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
| WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| BR112013020841B8 (pt) | 2011-02-18 | 2021-11-30 | Ying Ko Sai | Processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos |
| WO2012174158A2 (en) | 2011-06-14 | 2012-12-20 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
| RU2015120181A (ru) * | 2012-11-13 | 2017-01-10 | Гордаген Фармасьютикалз Пти Лтд | Чресслизистая доставка токотриенола |
-
2013
- 2013-11-13 RU RU2015120181A patent/RU2015120181A/ru not_active Application Discontinuation
- 2013-11-13 NZ NZ628963A patent/NZ628963A/en unknown
- 2013-11-13 CN CN201380022566.8A patent/CN104582700B/zh active Active
- 2013-11-13 PT PT138544408T patent/PT2919777T/pt unknown
- 2013-11-13 EP EP13854440.8A patent/EP2919777B1/en active Active
- 2013-11-13 PL PL13854440T patent/PL2919777T3/pl unknown
- 2013-11-13 ES ES13854440T patent/ES2778065T3/es active Active
- 2013-11-13 MY MYPI2015000856A patent/MY177940A/en unknown
- 2013-11-13 JP JP2015540965A patent/JP6460998B2/ja active Active
- 2013-11-13 KR KR1020147022626A patent/KR20150082109A/ko not_active Application Discontinuation
- 2013-11-13 WO PCT/AU2013/001310 patent/WO2014075135A1/en active Application Filing
- 2013-11-13 BR BR112015010703-6A patent/BR112015010703B1/pt active IP Right Grant
- 2013-11-13 PE PE2015000622A patent/PE20151518A1/es not_active Application Discontinuation
- 2013-11-13 US US14/435,607 patent/US10675265B2/en active Active
- 2013-11-13 CA CA2891164A patent/CA2891164C/en active Active
- 2013-11-13 CN CN202011457257.1A patent/CN112451518A/zh active Pending
- 2013-11-13 DK DK13854440.8T patent/DK2919777T3/da active
- 2013-11-13 AU AU2013344817A patent/AU2013344817B2/en active Active
- 2013-11-13 SG SG11201503640WA patent/SG11201503640WA/en unknown
-
2015
- 2015-05-10 IL IL238727A patent/IL238727A0/en unknown
- 2015-05-11 IN IN4006DEN2015 patent/IN2015DN04006A/en unknown
- 2015-05-11 PH PH12015501048A patent/PH12015501048A1/en unknown
- 2015-06-10 ZA ZA2015/04191A patent/ZA201504191B/en unknown
- 2015-08-14 HK HK15107895.4A patent/HK1207295A1/xx unknown
-
2018
- 2018-09-21 JP JP2018177662A patent/JP6978392B2/ja active Active
-
2020
- 2020-04-23 US US15/929,297 patent/US11331302B2/en active Active
- 2020-10-09 JP JP2020171008A patent/JP2021008509A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151518A1 (es) | Administracion transmucosa de tocotrienol | |
| CY1122624T1 (el) | Θεραπεια συνδυασμου του καρκινου | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| DK3826632T3 (da) | Terapeutiske sammensætninger, der omfatter deutererede eller delvist deutererede n,n-dimethyltryptaminforbindelser | |
| CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| CU20170144A7 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror | |
| CU24496B1 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| CO2020015153A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
| CY1123091T1 (el) | Σκευασμα στοματικου δισκιου που αποτελειται απο τον σταθερο συνδυασμο της ροσουβαστατινης και της εζετιμιμπης για τη θεραπεια της υπερλιπιδαιμιας και των καρδιοαγγειακων νοσων | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| CL2015000119A1 (es) | El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |